Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : JBI-802
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Jubilant Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Jubilant Therapeutics and OneThree Biotech Collaborate to Advance Precision Oncology
Details : As part of the collaboration, Jubilant Therapeutics sought to determine the mechanism for its potentially first-in-class dual epigenetic inhibitor targeting melanoma, myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML) and select solid tumor...
Product Name : JBI-802
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 11, 2020
Lead Product(s) : JBI-802
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Jubilant Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration